BFRIW - Biofrontera Inc. Warrants Stock Overview & Analysis

Key Statistics

Market Cap

—

P/E Ratio

—

EPS

$-1.30

Beta

0.82

52W High

$0.28

52W Low

$0.02

50-Day MA

$0.00

200-Day MA

$0.00

Dividend Yield

—

Profit Margin

-25.70%

Forward P/E

—

PEG Ratio

—

About Biofrontera Inc. Warrants

Biofrontera Inc. is a biopharmaceutical company focused on the development and commercialization of innovative dermatological therapies, particularly in the field of skin cancer treatments. Its flagship product, Ameluz, is recognized as a leading therapy for actinic keratosis, complemented by an advanced photodynamic therapy system that enhances patient outcomes. With a strong commitment to expanding its product range and market footprint, Biofrontera is well-positioned to meet the growing global demand for effective skin cancer solutions while exploring strategic partnerships to drive its growth strategy in the competitive healthcare landscape.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)	$43.20M
Gross Profit (TTM)	$33.39M
EBITDA	$-10.56M
Operating Margin	-39.00%
Return on Equity	-339.00%
Return on Assets	-32.40%
Revenue/Share (TTM)	$3.97
Book Value	$0.51
Price-to-Book	—
Price-to-Sales (TTM)	—
EV/Revenue	-
EV/EBITDA	—
Quarterly Earnings Growth (YoY)	0.00%
Quarterly Revenue Growth (YoY)	17.40%
Shares Outstanding	0
Float	$9.08M
% Insiders	0.00%
% Institutions	0.00%

Historical Volatility

HV 10-Day

275.07%

HV 20-Day

268.74%

HV 30-Day

273.37%

HV 60-Day

263.30%

HV Rank

—

Volatility is currently expanding

Latest News

Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026.

GlobeNewsWire5/21/2026Neutral